Document:

EX-10.15

 Exhibit 10.15 

LICENSE AGREEMENT 
 This License Agreement
(“Agreement”) is entered into and effective as of August 5, 2010 (“Effective Date”) by and between Integrated DNA Technologies, Inc., an Iowa corporation, with offices at 1710 Commercial Park, Coralville, Iowa, 52242
(“IDT”) and Great Basin Scientific, with offices at 2441 South 3850 West, West Valley City, Utah 84120, Suite A, 
 WHEREAS, IDT is the owner of
the patent applications listed in Appendix A of this agreement attached hereto and made apart hereof; and 
 WHEREAS, GBS wishes to obtain a license under
the patent and patent applications and any patents derived therefrom to use the compositions and methods described and claimed therein; 
 NOW, THEREFORE,
in consideration of the mutual covenants contained herein and intending to be legally bound hereby, the parties agree as follows: 
 1. Definitions. 

1.1. “Excluded Fields” shall mean any application or field not expressly granted in the definition of Licensed Fields, including without limitation
any (i) clinical and non-clinical products or applications that involve or include the polymerase chain reaction, (ii) any and all forensics & human identity applications; (iii) environmental testing, agricultural plant
applications, animal testing and positive trait breeding applications; (iv) food testing and genetically-modified organism testing applications, and (v) any and all bio-security applications. 

1.2. “Exclusive Field” shall mean the helicase-dependent amplification and detection of diagnostic targets in human in-vitro diagnostics, but
excluding all oncology and human papilloma virus targets or markers. Human in-vitro diagnostics shall mean detection of targets that cause human disease, whether samples are derived from a human or from viral, bacterial, or fungal pathogens or
samples are derived from the hospital or point of care environment, including screening in said environment for said pathogens. Additionally human in-vitro diagnostics shall mean detection of targets that determine predisposition to disease or may
predict response to potential treatment, excluding oncology and HPV targets. For purposes of clarity, IDT shall not license any Third-Party in the Exclusive Field. 

1.3. “Licensed Fields” shall mean use of the Licensed products in the Exclusive Field and the Non-Exclusive Field, but expressly not the
Excluded Fields. 
 1.4. “Licensed Patent Rights” means and includes the patent applications listed in Appendix A, and any patent or
patents issued therefrom or claiming priority thereto, and any reissues, reexaminations, divisions, continuations, continuations-in-part and extensions thereof, and any applications and patents in foreign countries derived or claiming priority
therefrom. 
 1.5. “Licensed Products” means and includes any product or service the manufacture, import, sale, offer for sale and/or use of which
would infringe one or more of the Licensed Patent Rights, but for the license granted herein. 
 1.6. “Licensed Territory” all those territories
wherein the Licensed Patent Rights may become or remain valid and enforceable. 
  

[MATERIAL FROM THIS EXHIBIT HAS BEEN REDACTED PURSUANT TO A REQUEST FOR 

CONFIDENTIAL TREATMENT] 

  
 1 

 1.7. “Net Sales” shall mean the actual gross amount invoiced by GBS for sales or other commercial
disposition of a Licensed Product to Third Parties, less the following deductions with respect to such sales or services: 
 a) any rebates, quantity, trade
and cash discounts, and other usual and customary discounts to customers; 
 b) compulsory payments and rebates, actually paid or deducted; 

c) retroactive price reductions, credits or allowances actually granted upon rejections or returns of Licensed Products, including for recalls or damaged
goods; 
 d) freight, postage, shipping and insurance charges actually allowed or paid for delivery of Licensed Products, to the extent included in the
gross sales price; 
 e) sales taxes, excise taxes, use taxes, import/export duties or other governmental charges actually due or incurred with respect to
such sales, including without limitation value-added taxes; 
 f) discounts and performance discounts to the extent that such discounts are associated with
the Licensed Products together with other products of Licensee and its Affiliates, and to the extent that such discounts cannot be attributed only to the Licensed Products. Such discounts and performance discounts will be allocated to the Licensed
Products on a reasonable pro rata basis (based on the amount of the sales of products by Licensee and its Affiliates prior to discount); and 
 g)
charge-back payments and rebates granted to managed health care organizations or to federal, state and local governments, their respective agencies, purchasers or reimbursers; all as incurred in the ordinary course of business in type and amount
consistent with good industry practice and determined in accordance with generally accepted accounting principles on a basis consistent with Licensee’s audited consolidated financial statements. 

1.8. “Non-Exclusive Field” shall mean the helicase-dependent amplification and detection of oncology and human papilloma virus targets or markers in
human in-vitro diagnostics conducted in the point-of-care setting, including the physician’s office laboratory, which may direct treatment decisions. Human in-vitro diagnostics shall mean detection of targets that cause human disease, whether
samples are derived from a human or from viral, bacterial, or fungal pathogens or or samples are derived from the hospital or point of care environment, including screening in said environment for said pathogens. Additionally, human in-vitro
diagnostics shall mean detection of targets that determine predisposition to disease or may predict response to potential treatment. 
 1.9. “Third
Parties” means any entity other than IDT, GBS or their affiliates, which shall include only those entities that legally control or are under the legal control of IDT or GBS. 

2. License 
 2.1. License Grant. IDT hereby grants to GBS a
limited, non-transferable, royalty-bearing license under the Licensed Patent Rights to make, have made, use, import, offer to sell and sell Licensed Products in the Licensed Fields in the Licensed Territory. The license granted to GBS shall not
restrict IDT from doing any act itself, or from granting any additional rights in fields other than the Exclusive Field. 
 2.2. IDT Warranty. IDT warrants
only that it has the right to grant this license under the Licensed Patent Rights. IDT expressly disclaims any other warranty regarding the validity or eriforceability of the Licensed Patent Rights, or non-infringement regarding the Licensed
Products. 
  
 [MATERIAL FROM THIS EXHIBIT HAS BEEN REDACTED PURSUANT TO
A REQUEST FOR 
 CONFIDENTIAL TREATMENT] 

  
 2 

 2.3. Limited License. Nothing herein shall be construed as granting GBS, by implication, estoppel or otherwise,
any license or other right to any other intellectual property owned, controlled by and/or invented by IDT or any of the inventors of the Licensed Patent Rights, or to grant to GBS any right or license, other than the limited license under the
Licensed Patent Rights expressly granted herein. 
 2.4. No Supply Terms. GBS acknowledges that nothing in this Agreement obligates or is intended to
obligate IDT to manufacture or sell Licensed Products, oligonucleotides, enzymes or reaction mixtures containing any of the same to GBS, to GBS’s Affiliates or to GBS’s customers. Any such obligation must be the subject matter of a
separate, written agreement of the parties. 
 3. Consideration/Fees 

3.1. Initial License Fee. GBS shall pay to IDT a non-refundable, non-creditable, initial license fee of ******** to IDT within ten (10) days of the
Effective Date of this Agreement. The failure of GBS to timely pay the initial license fee shall be cause for immediate termination of this Agreement by IDT. 

3.2. Milestone License Fee. GBS shall pay an additional non-refundable, non-creditable, license fee of ******** to IDT a upon any closing of a transaction
which results in GBS receiving at least $2.5 million in cash or cash equivalents in exchange for GBS equity (stock), debt obligations, or other forms of consideration, other than the sale of GBS products which are sold at market prices (a
“Funding Event”) that may occur after the execution of this agreement. If a Funding Event has not occurred by the first anniversary date of this Agreement, then GBS shall pay to IDT within then (10) business days of the first
anniversary date, an additional non-refundable, non-creditable, license fee of ********. In such an event, GBS shall make a final additional non-refundable, non-creditable, license fee payment of ******** to IDT upon the earlier of (i) the 18
month anniversary date of this Agreement, or (ii) a Funding Event. For the avoidance of doubt, the total amount of license fees GBS is obligated to pay pursuant to 3.2 is ********, and the latest that the total licensee can be paid to IDT is
eighteen months following the Effective Date. The failure of GBS to timely pay the license fees described in this 3.2, or any installment payment described herein shall be cause for immediate termination of this Agreement by IDT. 

3.3. Royalties. GBS shall pay to IDT the royalty identified on Appendix B for sales of Licensed Products under this Agreement. GBS agrees to deliver IDT
within sixty (60) days after the end of each calendar quarter, a report setting forth the Net Sales for the previous calendar quarter with respect to which payment is due under Section 3.2 above. Each report shall contain a) the number or
quantity of Licensed Products sold in the Territory; b) the calculation of Net Sales; c) total royalty payable on Net Sales in U.S. Dollars, in sufficient detail to permit IDT to confirm the accuracy of the foregoing. If no amounts are due to IDT
for any such Calendar Quarter, the report shall so state. Concurrently with the making of each such report GBS shall pay to IDT any payments due pursuant to this 3.3 and Appendix B, and shall deliver both the report and payment to the address
specified in 8.6 herein. 
 4. Term and Termination 
 4.1.
Term. The term of this Agreement shall be until the last to expire of any patent within the Licensed Patent Rights, unless sooner terminated as provided herein. 

4.2. Material Breach. If GBS materially defaults in rendering its license fees or royalties, or otherwise is in material breach of or in material default
under any other provision of this Agreement, IDT may 
  
 [MATERIAL FROM
THIS EXHIBIT HAS BEEN REDACTED PURSUANT TO A REQUEST FOR 
 CONFIDENTIAL TREATMENT] 

  
 3 

 
terminate this Agreement by giving GBS written notice of its election to terminate as of a stated date not less than thirty (30) days from the date of mailing such notice, and if GBS shall
fail to repair such breach or default prior to the stated date of termination, this Agreement shall then terminate. Such termination, however, shall not relieve GBS of its obligations incurred prior to such termination and shall not impair any of
the rights that IDT acquired prior to such date. 
 4.3. Termination by Patent Invalidation. This Agreement shall terminate if at any time all claims of all
patents within the Licensed Patent Rights are declared invalid or void by any court of final resort or in a judgment from which no appeal is or can be taken. Notwithstanding any such termination, all license fees and royalties received by lDT are
and shall remain non-refundable. 
 4.4. Elective Termination. GBS may terminate this Agreement for any reason by giving ninety (90) days prior written
notice to IDT, and by ceasing to make, advertise, promote or sell any and all Licensed Products. 
 5. Markings / Trademarks / Publicity 

5.1 Marking of Licensed Products. All Licensed Products sold by GBS under this Agreement, shall include on the product itself or on materials included with
each shipment of Licensed Product, the following or substantially similar statement: “Sold under license of patents and/or patents pending from Integrated DNA Technologies, Inc.”. 

5.2 Publicity. Neither GBS, nor IDT shall make any public announcement of this Agreement or any of its terms without the prior written consent of the other
party. The Parties further agree that in the event that either party wishes to prepare and publicly disseminate a press release announcing the grant of rights referenced herein, that party shall provide the other party a written draft of such
release prior to the intended date of release. The parties shall each have the right to make reasonable modifications to any such press release, and no announcement shall be released unless and until both parties have agreed in writing to the form
and content of the release. 
 6. Warranties/Disclaimers 
 6.1.
General Disclaimer. ANY AND ALL LICENSED PATENT RIGHTS MADE AVAILABLE BY lDT TO GBS AND ITS AFFILIATES ARE LICENSED OR MADE AVAILABLE “AS IS.” IDT MAKES NO REPRESENTATIONS, WARRANTIES, OR COVENANTS TO GBS OR ITS AFFILIATES CONCERNING THE
LICENSED PATENT RIGHTS, INCLUDING WITHOUT LIMITATION THEIR VALIDITY, OR THAT THEY WILL ISSUE, WHETHER IN THEIR PRESENT FORM OR WITH SUBSTANTIAL MODIFICATION, OR CONCERNING THE NEED FOR GBS AND ITS AFFILIATES TO OBTAIN ADDITIONAL LICENSES FROM THIRD
PARTIES TO USE LICENSED PRODUCTS IN THE LICENSED FIELD. IDT DISCLAIMS ALL WARRANTIES, EXPRESS, STATUTORILY OR IMPLIED, INCLUDING ANY IMPLIED WARRANTIES OF QUALITY, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR NONINFRINGEMENT, AND ASSUMES NO
RESPONSIBILITIES WHATSOEVER WITH RESPECT TO MANUFACTURE, USE, SALE, OR OTHER DISPOSITION BY GBS OR ITS AFFILIATES OR OTHER TRANSFEREES OF PRODUCTS OR PROCESSES INCORPORATING OR MADE BY USE OF INVENTIONS LICENSED UNDER THIS AGREEMENT. 

6.2. Joint Waivers of Purchase and Sale Obligations. By virtue of executing this Agreement, neither GBS nor its Affiliates commit to purchase oligonucleotides
manufactured by IDT. By virtue of executing this Agreement IDT does not commit to sell or otherwise obligate itself to manufacture oligonucleotides for GBS or its Affiliates. Notwithstanding the foregoing, it is the intent of the parties hereto to
negotiate terms of a separate oligonucleotide supply agreement. 
  

[MATERIAL FROM THIS EXHIBIT HAS BEEN REDACTED PURSUANT TO A REQUEST FOR 

CONFIDENTIAL TREATMENT] 

  
 4 

 6.3. IDT Disclaimer Regarding Clinical Uses of Licensed Products. Unless otherwise specified in a separate
written supply agreement between the parties, IDT does not warrant, guarantee or make any representations above and beyond the oligo criteria set forth in a separate supply agreement, if any, regarding the use of Licensed Products in clinical,
diagnostic or any other application, or with respect to the correctness, accuracy, reliability of the results of any such use. UNLESS OTHERWISE SPECIFIED IN A SEPARATE WRITTEN SUPPLY AGREEMENT BETWEEN THE PARTIES, IDT SHALL NOT BE LIABLE FOR, AND
GBS ASSUMES THE ENTIRE RISK AS TO THE RESULTS OBTAINED BY GBS OR ITS AFFILIATES FROM THE USE OF OLIGONUCLEOTIDES AND/OR LICENSED PRODUCTS IN THE LICENSED FIELD. UNLESS OTHERWISE SPECIFIED IN A SEPARATE WRITTEN SUPPLY AGREEMENT BETWEEN THE PARTIES,
GBS FURTHER ACKNOWLEDGES THAT GBS, AND NOT IDT, IS SOLELY RESPONSIBLE FOR ANY WARRANTY OR GUARANTEE MADE TO COLLABORATORS OR CUSTOMERS OF GBS OR ITS AFFILIATES WITH RESPECT TO THE USE OF OLIGONUCLEOTIDES AND/OR LICENSED PRODUCTS IN THE LICENSED
FIELD. 
 7. Indemnification and Infringement 
 7.1.
Indemnification of IDT. GBS shall defend, indemnify and hold harmless IDT, its employees, officers, trustees, agents, the inventors of the Licensed Patent and their successors and assigns (each an “IDT Indemnitee”), from and against any
and all liabilities, damages, settlements, penalties, fines, costs or expenses (including, without limitation, reasonable attorneys’ fees and other expenses of litigation) arising out of any claim, complaint, suit, proceeding or cause of action
brought against an IDT Indemnitee by a Third Party (any of the foregoing, an “IDT Claim”) alleging damage arising from or occurring as a result of the activities performed by or under authority of GBS and/or its Affiliates in connection
with the exercise of its licenses and rights hereunder, except to the extent caused by the negligence or willful misconduct of IDT or any IDT Indemnitee or related to the breach of any representation, warranty, or covenant by IDT hereunder. IDT at
all times reserves the right to select and retain counsel of its own at its own expense to defend lDT’s interests with respect to such IDT Claim. The foregoing indemnity obligation is conditioned upon the IDT Indemnitee promptly notifying GBS
of the IDT Claim, allowing GBS to control the defense or settlement of such IDT Claim, and providing GBS with reasonable assistance in the defense or settlement of such IDT Claim, subject to GBS reimbursing IDT for its reasonable out-of-pocket
expenses incurred in providing such assistance. 
 7.2. Indemnification of GBS. IDT shall defend, indemnify and hold harmless GBS, its Affiliates, and their
respective employees, officers, trustees, agents and their successors and assigns (each a “GBS Indemnitee”), from and against any and all liabilities, damages, settlements, penalties, fines, costs or expenses (including, without
limitation, reasonable attorneys’ fees and other expenses of litigation) arising out of any claim, complaint, suit, proceeding or cause of action brought against an GBS Indemnitee by a Third Party (any of the foregoing, a “GBS Claim”)
alleging damage arising from or occurring as a result of the activities performed by or under authority of IDT and/or its Affiliates in connection with the exercise of its rights hereunder or performance of its obligations hereunder, except as
subject to Article 6 herein, and except to the extent any GBS Claim is caused by the negligence or willful misconduct of GBS or any GBS Indemnitee or related to the breach of any representation, warranty, or covenant by GBS hereunder. GBS at all
times reserves the right to select and retain counsel of its own at its own expense to defend GBS’s interests with respect to such GBS Claim. The foregoing indemnity obligation is conditioned upon the GBS Indemnitee promptly notifying IDT of
the GBS Claim, allowing IDT to control the defense or settlement of such GBS Claim, and providing IDT with reasonable assistance in the defense or settlement of such GBS Claim, subject to IDT reimbursing GBS for its reasonable out-of-pocket expenses
incurred in providing such assistance. 
  
 [MATERIAL FROM THIS EXHIBIT
HAS BEEN REDACTED PURSUANT TO A REQUEST FOR 
 CONFIDENTIAL TREATMENT] 

  
 5 

 7.3. Infringement by Third Persons. GBS shall promptly advise IDT in writing of any infringement or suspected
infringement of any of the rights under the Licensed Patent Rights. In the case of any infringement of any Licensed Patent Rights by any third party (an “Infringer”) during the term of this Agreement, IDT shall have the exclusive right
under IDT’s control and at IDT’s expense to prosecute any third party infringement of the Licensed Patent Rights. Subject to IDT’s control of any such proceeding, GBS shall have the right, at its own expense and using counsel of its
choosing, to participate in such proceeding. GBS shall assist as reasonably requested in taking any such action against any such Infringer at IDT’s expense, unless GBS has stopped or put on hold the development of all Licensed Products. Any
amount recovered by or reimbursed to IDT as a result of any action taken by IDT under this Section (including, without limitation, from any settlement or other voluntary disposition thereof) shall be retained by IDT. 

8. General 
 8.1. Assignment. This Agreement shall not be
assigned by GBS except with the written consent of IDT, except that GBS may assign this Agreement without IDT’s written consent in connection with a merger, acquisition, change of control, reorganization or sale of all or substantially all of
the assets of GBS. IDT may assign this Agreement at its sole and independent discretion. IDT’s unrestricted right to out-license the Licensed Patent Rights in fields other than the Exclusive Field, shall not in any way be limited by this
Agreement. 
 8.2. Force Majeure. In the event either party hereto is prevented from or delayed in the performance of any of its obligations hereunder by
reason of acts of God, war, strikes, riots, storms, fires, or any other cause whatsoever beyond the reasonable control of the party, the party so prevented or delayed shall be excused from the performance of any such obligation to the extent and
during the period of such prevention or delay. 
 8.3. Entire Agreement. This Agreement constitutes the entire agreement by, between and among the parties
and the terms hereof cannot be modified, changed, discharged or terminated except in writing signed by the parties hereto. 
 8.4. Waiver. Neither party
shall be deemed to have waived or released any of its rights or interest in this Agreement, unless such waiver or release is set forth in writing. No waiver by either party of any default by the other shall constitute a waiver of a like, similar or
other default thereafter. 
 8.5. Choice of Law. This Agreement shall be governed by and interpreted in accordance with the laws of the State of lowa,
exclusive of its choice of law principles. 
 8.6. Notices. For the purposes of this Agreement and until written notice of change of address shall be given,
any notices required or permitted to be given under the terms of this Agreement shall be addressed by first class United States mail to the parties as follows: 

If to IDT: 
 Integrated DNA Technologies, Inc 

Attn: Legal Department 
 1710 Commercial Park 

Coralville, Iowa 
 52241 

Fax: 319-626-8444 
  

[MATERIAL FROM THIS EXHIBIT HAS BEEN REDACTED PURSUANT TO A REQUEST FOR 

CONFIDENTIAL TREATMENT] 

  
 6 

 If to GBS: 
 Great
Basin Scientific 
 2441 South 3850 West 
 Suite A 

West Valley City, Utah 84120 
 8.7. Independent Contractors. The
relationship of the parties established by this Agreement is that of independent contractors. Nothing in this Agreement shall be construed to create any other relationship between IDT and GBS. Neither party shall have any right, power or authority
to assume, create or incur any expense, liability or obligation, express or implied, on behalf of the other party. 
 8.8. Interpretation of Terms. If any
provisions of this Agreement are or shall come into conflict with the laws or regulations of any jurisdiction or any governmental entity having jurisdiction over the parties or this Agreement, those provisions shall be deemed automatically deleted,
if such deletion is allowed by relevant law, and the remaining terms and conditions of this Agreement shall remain in full force and effect. If such a deletion is not so allowed or if such a deletion leaves terms thereby made clearly illogical or
inappropriate in effect, the parties agree to substitute new terms as similar in effect to the present terms of this Agreement as may be allowed under the applicable laws and regulations. This Agreement has been subject to negotiation by both
parties and in no circumstances shall it be construed against the drafter. 
 8.9. Counterparts. This Agreement may be executed in counterparts, each of
which shall be deemed an original, but both of which together shall constitute one and the same instrument. Facsimile signatures by authorized agents of either party of this Agreement shall be considered as having the same effect as original
signatures. 
 IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement effective on the date first indicated above. 

 

									
	GREAT BASIN SCIENTIFIC	 		 	INTEGRATED DNA TECHNOLOGIES, INC.
					
	By:	 	 /s/ Robert Jenison
	 		 	By:	 	 /s/ Roman Terrill

	Name:	 	Robert Jenison	 		 	Name:	 	Roman Terrill
	Title:	 	Chief Technology Officer	 		 	Title:	 	General Counsel
	Date:	 	8/24/2010	 		 	Date:	 	8-23-2010

  
 [MATERIAL FROM THIS EXHIBIT HAS BEEN
REDACTED PURSUANT TO A REQUEST FOR 
 CONFIDENTIAL TREATMENT] 

  
 7 

 Appendix A 

[Redacted] 
  

[MATERIAL FROM THIS EXHIBIT HAS BEEN REDACTED PURSUANT TO A REQUEST FOR 

CONFIDENTIAL TREATMENT] 

  
 8 

 Appendix B 

“Royalty Rate” 
 GBS shall pay to IDT
one of the following royalty rates on Net Sales of Licensed Products, in a time and manner consistent with Article 3.3 of the Agreement. 
 (1) Base Rate:
********* 
 The Base Rate shall be the royalty rate if no additional license fees are paid by GBS to IDT other than those specified in 3.1 and 3.2 of the
Agreement. 
 (2) Lower Rate: : ********* 
 The Lower Rate
shall be the royalty rate if, on or before the second anniversary date of this agreement, GBS pays to IDT ********* in addition to license fees paid by GBS to IDT specified in 3.1 and 3.2 of the Agreement. 

For the avoidance of doubt, GBS would have to pay a total of ********* in license fees by the second anniversary date of the Agreement to earn the right to
pay a ****** royalty on Net Sales of Licensed Product. 
 (3) Lowest Rate: *** 

The Lowest Rate shall be the royalty rate if, on or before the second anniversary date of this agreement, GBS pays to IDT *********in addition to license fees
paid by GBS to IDT specified in 3.1 and 3.2 of the Agreement. 
 For the avoidance of doubt, GBS would have to pay a total of ********* in license fees by
the second anniversary date of the Agreement to earn the right to pay a ********* royalty on Net Sales of Licensed Product. 
  

[MATERIAL FROM THIS EXHIBIT HAS BEEN REDACTED PURSUANT TO A REQUEST FOR 

CONFIDENTIAL TREATMENT] 

  
 9 

 FIRST AMENDMENT TO LICENSE AGREEMENT 

This First Amendment (“Amendment”) entered into as of February 21, 2012 (“Effective Date”) is made by and between Great Basin
Scientific, an organization having its principal place of business at 405 South Main Street, Suite 810, Salt Lake City, UT 84111 (“GBS”), and Integrated DNA Technologies, Inc., an organization having its principal place of business at 1710
Commercial Park, Coralville, lA 52241 (“lDT”). 
 WHEREAS, GBS and lDT (the “Parties”) have entered into a License Agreement, which was
made effective August 5, 2010 (the “Agreement”), 
 WHEREAS, GBS has already tendered a ****** milestone payment on or about August 5,
2011, pursuant to Section 3.2 of the Agreement; and 
 WHEREAS, the Parties to the Agreement wish to amend the Agreement pursuant to Section 8.3
thereof, 
 NOW, THEREFORE, in consideration of the promises and the mutual covenants contained herein, the parties agree as follows: 

1. Section 3.2 of the Agreement is deleted and replaced with the following: 

3.2 Milestone License Fee. GBS shall pay, in addition to ******* already paid to IDT as a license fee, an additional non-refundable,
non-creditable, license fee of ***** to IDT within (i) thirty (30) days of any closing of a transaction which results in GBS receiving at least $2.5 million in cash or cash equivalents in exchange for GBS equity (stock), debt obligations,
or other forms of consideration, other than the sale of GBS products which are sold at market prices (a “Funding Event”), or (ii) November 20, 2012. For the avoidance of doubt, the highest total amount of license fees GBS is
obligated to pay pursuant to 3.2 is *********, and the latest that the total licensee can be paid to lDT is November 20, 2012. The failure of GBS to timely pay the license fees described in this 3.2, or any installment payment described herein
shall be cause for immediate termination of this Agreement by IDT. 
 2. Appendix B of the Agreement is deleted and replaced with the following. 

Appendix B 
 “Royalty
Rate” 
 GBS shall pay to IDT one of the following royalty rates on Net Sales of Licensed Products, in a time and manner consistent with Article 3.3 of
the Agreement. 
 (1) Base Rate: ***** 
 The Base Rate shall
be the royalty rate if no additional license fees are paid by GBS to IDT other than those specified in 3.1 and 3.2 of the Agreement. 
 (2) Lower Rate:
****** 
 The Lower Rate shall be the royalty rate if, on or before April 20, 2013, GBS pays to IDT ********* in addition to license fees paid by GBS
to IDT specified in 3.1 and 3.2 of the Agreement. 
  
 [MATERIAL FROM
THIS EXHIBIT HAS BEEN REDACTED PURSUANT TO A REQUEST FOR 
 CONFIDENTIAL TREATMENT] 

  
 10 

 For the avoidance of doubt, GBS would have to pay a total of ******* in license fees by the second anniversary
date of the Agreement to earn the right to pay a ***** royalty on Net Sales of Licensed Product. 
 (3) Lowest Rate: ****** 

The Lowest Rate shall be the royalty rate if, on or before April 20, 2013, GBS pays to IDT ******** in addition to license fees paid by GBS to IDT
specified in 3.1 and 3.2 of the Agreement. 
 For the avoidance of doubt, GBS would have to pay a total of ********* in license fees by the second
anniversary date of the Agreement to earn the right to pay a ***** royalty on Net Sales of Licensed Product. 
 3. Except as expressly stated above, the
remainder of the Agreement shall remain unamended and in full force and effect, in accordance with its terms. 
 IN WITNESS WHEREOF, the parties have
caused this Amendment to be executed as of the date written above. 
  

									
	Great Basin Scientific	 		 	Integrated DNA Technologies, Inc.
				
	Signature:	 	 /s/ Robert Jenison
	 		 	 /s/ Roman Terrill

	Name:	 	Robert Jenison	 		 	Roman Terrill
	Title:	 	Chief Technology Officer	 		 	General Counsel
	Date:	 	3/22/12	 		 	Date:	 	3-5-2012

  
 [MATERIAL FROM THIS EXHIBIT HAS BEEN
REDACTED PURSUANT TO A REQUEST FOR 
 CONFIDENTIAL TREATMENT] 

  
 11 

 SECOND AMENDMENT TO LICENSE AGREEMENT 

This Second Amendment (“Amendment”) entered into as of October 17, 2012 (“Effective Date”) is made by and between Great Basin
Scientific, an organization having its principal place of business at 405 South Main Street, Suite 810, Salt Lake City, UT 84111 (“GBS”), and Integrated DNA Technologies, Inc., an organization having its principal place of business at 1710
Commercial Park, Coralville, lA 52241 (“lDT”). 
 WHEREAS, GBS and IDT (the “Parties”) have entered into a License Agreement, which was
made effective August 5, 2010 (the “Agreement”), and 
 WHEREAS, the Parties have executed a First Amendment to the License Agreement, which
was made effective February 21, 2012, (the “First Amendment”), 
 WHEREAS, the Parties to the Agreement wish to further amend the Agreement
pursuant to Section 8.3 thereof, 
 NOW, THEREFORE, in consideration of the promises and the mutual covenants contained herein, the parties agree as
follows: 
 1. Section 3.2 of the Agreement, as amended by the First Amendment, is hereby deleted and replaced with the following: 

3.2 Milestone License Fee. On the first anniversary date of this Agreement, GBS paid to lDT, a non-refundable, non-creditable,
license fee of ***** . GBS shall pay to IDT an additional non-refundable, non-creditable, license fee totaling *****, in ten (10) equal monthly installments of *********. Installment payments shall be made on the first day of each calendar
month commencing December 1, 2012, and ending September 1, 2013. For the avoidance of doubt, the total amount of license fees GBS is obligated to pay pursuant to 3.2 is ********. The failure of GBS to timely pay installment payment
described herein shall be cause for immediate termination of this Agreement by lDT. 
 2. Except as expressly stated above, the remainder of
the Agreement shall remain unamended and in full force and effect, in accordance with its terms. 
 IN WITNESS WHEREOF, the parties have caused this
Amendment to be executed as of the date written above. 
  

									
	Great Basin Scientific	 		 	Integrated DNA Technologies, Inc.
					
	 Signature:
	 	 /s/ Rob Jenison
	 		 	Signature:	 	 /s/ Roman Terrill

	Name:	 	Rob Jenison	 		 	Roman Terrill
	Title:	 	Chief Technology Officer	 		 	General Counsel
	Date:	 	11/13/2012	 		 	Date: 11-13-2012

  
 [MATERIAL FROM THIS EXHIBIT HAS BEEN
REDACTED PURSUANT TO A REQUEST FOR 
 CONFIDENTIAL TREATMENT] 

  
 12 

 THIRD AMENDMENT TO LICENSE AGREEMENT 

This Third Amendment (“Amendment”) entered into as of February 21, 2013 (“Effective Date”) is made by and between Great
Basin Scientific, an organization having its principal place of business at 405 South Main Street, Suite 810, Salt Lake City, UT 84111 (“GBS”), and Integrated DNA Technologies, Inc., an organization having its principal place of
business at 1710 Commercial Park, Coralville, IA 52241 (“IDT”). 
 WHEREAS, GBS and IDT (the “Parties”) have
entered into a License Agreement, which was made effective August 5, 2010 (the “Agreement”), and 
 WHEREAS, the Parties have
executed a First Amendment to the License Agreement, which was made effective February 21, 2012, (the “First Amendment”), and 

WHEREAS, the Parties have executed a Second Amendment to the Licensing Agreement, which was made effective February 21, 2012, (the “Second
Amendment”), and 
 WHEREAS, the Parties to the Agreement wish to further amend the Agreement pursuant to Section 8.3 thereof, 

NOW, THEREFORE, in consideration of the promises and the mutual covenants contained herein, the parties agree as follows: 

 

	 	1.	The following Section 3.4 shall be added to the Agreement. 

 3.4 Third Amendment
Fee. On or before April 20, 2013, GBS shall pay to IDT, a non-refundable, non-creditable, amendment fee of *********. 
  

	 	2.	Appendix B of the Agreement is hereby deleted in its entirety and replaced with the following: 

Appendix B 
 “Royalty
Rate” 
 GBS shall pay to IDT one of the following royalty rates on Net Sales of Licensed Products, in a time and manner consistent with Article 3.3 of
the Agreement. 
  

	 	(1)	Base Rate: ***** 

 The Base Rate shall be the royalty rate if no additional license fees are paid by GBS to IDT
other than those specified in 3.1 and 3.2 of the Agreement. 
  

	 	(2)	Lower Rate: **** 

 The Lower Rate shall be the royalty rate if on or before April 20, 2014, GBS pays to
IDT ******* in addition to the fees paid by GBS to IDT specified in 3.1, 3.2 and 3.4 of the Agreement. 
  

[MATERIAL FROM THIS EXHIBIT HAS BEEN REDACTED PURSUANT TO A REQUEST FOR 

CONFIDENTIAL TREATMENT] 

  
 13 

	 	(3)	Lowest Rate: ***** 

 The Lowest Rate shall be the royalty late if, on or before April 20, 2014, GBS pays
to IDT ******** in addition to the fees paid by GBS to IDT specified in 3.1, 3.2 and 3.4 of the Agreement. 
  

Except as expressly stated above, the remainder of the Agreement, as amended by the First and Second Amendment, shall remain unamended and in full force and
effect, in accordance with its terms. 
 IN WITNESS WHEREOF, the parties have caused this Amendment to be executed as of the date written above. 

 

					
	Great Basin Scientific	 		 	Integrated DNA Technologies, Inc.
			
	/s/ Rob Jenison	 		 	  

	Signature	 		 	Signature
			
	Rob Jenison, Chief Technology Officer	 		 	  

	Name & Title	 		 	Name & Title
			
	4/5/13	 		 	  

	Date	 		 	Date

  
 [MATERIAL FROM THIS EXHIBIT HAS BEEN
REDACTED PURSUANT TO A REQUEST FOR 
 CONFIDENTIAL TREATMENT] 

  
 14 

 FOURTH AMENDMENT TO LICENSE AGREEMENT 

This Fourth Amendment (“Amendment”) entered into as of March 19, 2014 (“Effective Date”) is made by and between Great
Basin Scientific, an organization having its principal place of business at 405 South Main Street, Suite 810, Salt Lake City, UT 84111 (“GBS”), and Integrated DNA Technologies, Inc., an organization having its principal place of
business at 1710 Commercial Park, Coralville, IA 52241 (“IDT”). 
 WHEREAS, GBS and IDT (the “Parties”) have
entered into a License Agreement, which was made effective August 5, 2010 (the “Agreement”), and 
 WHEREAS, the Parties have
executed a First Amendment to the License Agreement, which was made effective February 21, 2012, (the “First Amendment”), and 

WHEREAS, the Parties have executed a Second Amendment to the Licensing Agreement, which was made effective February 21, 2012, (the “Second
Amendment”), and 
 WHEREAS, the Parties have executed a Third Amendment to the Licensing Agreement, which was made Effective,
February 21, 2013, (the “Third Amendment”), and 
 WHEREAS, the Parties to the Agreement wish to further amend the Agreement
pursuant to Section 8.3 thereof, 
 NOW, THEREFORE, in consideration of the promises and the mutual covenants contained herein, the parties
agree as follows: 
  

	 	1.	The following Section 3.5 shall be added to the Agreement. 

 3.5 Fourth Amendment
Fee. On or before April 20, 2014, GBS shall pay to IDT, a non-refundable, non-creditable, amendment fee of ****. 
  

	 	2.	Appendix B of the Agreement is hereby deleted in its entirety and replaced with the following: 

Appendix B 
 “Royalty
Rate” 
 GBS shall pay to IDT one of the following royalty rates on Net Sales of Licensed Products, in a time and manner consistent with Article 3.3 of
the Agreement. 
  

	 	(1)	Base Rate: *** 

 The Base Rate shall be the royalty rate if no additional license fees are paid by GBS to IDT
other than those specified in 3.1 and 3.2 of the Agreement. 
  

[MATERIAL FROM THIS EXHIBIT HAS BEEN REDACTED PURSUANT TO A REQUEST FOR 

CONFIDENTIAL TREATMENT] 

  
 15 

	 	(2)	Lower Rate: *** 

 The Lower Rate shall be the royalty rate if on or before April 20, 2015, GBS pays to IDT
***** in addition to the fees paid by GBS to IDT specified in 3.1, 3.2, 3.4 and 3.5 of the Agreement. 
  

	 	(3)	Lowest Rate: ****** 

 The Lowest Rate shall be the royalty late if, on or before April 20, 2015, GBS pays
to IDT ****** in addition to the fees paid by GBS to IDT specified in 3.1, 3.2, 3.4 and 3.5 of the Agreement. 
  

Except as expressly stated above, the remainder of the Agreement, as amended by the First and Second Amendment, shall remain unamended and in full force and
effect, in accordance with its terms. 
 IN WITNESS WHEREOF, the parties have caused this Amendment to be executed as of the date written above. 

 

					
	Great Basin Scientific	 		 	Integrated DNA Technologies, Inc.
			
	/s/ Rob Jenison	 		 	  

	  
	 		 	
	Signature	 		 	Signature
			
	 Rob Jenison, CTO
	 		 	
	Name & Title	 		 	Name & Title
			
	 3/19/14
	 		 	  

	Date	 		 	Date

  
 [MATERIAL FROM THIS EXHIBIT HAS BEEN
REDACTED PURSUANT TO A REQUEST FOR 
 CONFIDENTIAL TREATMENT] 

  
 16EX-10.16

 Exhibit 10.16 

REIMBURSEMENT AGREEMENT 

THIS REIMBURSEMENT AGREEMENT (this “Agreement”) is entered into as of the
30th day of October 2013, by and between Great Basin Scientific, Inc., a Delaware corporation (“Great Basin”), and Utah Autism Foundation, a Utah non-profit corporation (the
“Foundation”). Great Basin and the Foundation (collectively, the “Parties”) are entering into this Agreement for purposes of setting forth the mutual understanding and agreement of the Parties with respect to the
Letter of Credit (as defined below). 
 WHEREAS, Great Basin has requested that the Foundation cause to be issued a letter of credit
on behalf of Great Basin for the benefit of certain creditors of Great Basin (the “Creditors”), and the Foundation has agreed to use commercially reasonable efforts to cause such letter of credit to be issued (together with any
replacement letter of credit issued for the benefit of Great Basin, the “Letter of Credit”): 
 WHEREAS, the Letter
of Credit will be delivered by Great Basin to one or more Creditors for the purpose of securing certain obligations of Great Basin to be incurred by Great Basin in the course of conducting its business; 

WHEREAS, in exchange for the Foundation causing the Letter of Credit to be issued on behalf of Great Basin, Great Basin has agreed to
reimburse the Foundation for all amounts paid or payable hereafter by the Foundation in connection with the Letter of Credit, including, without limitation, costs, fees and expenses associated with obtaining and maintaining the Letter of Credit.

 NOW, THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged, the Parties hereby agree as
follows: 
 1. Delivery of Letter of Credit. The Foundation agrees to use commercially reasonable efforts to cause a Letter of Credit
to be issued by Bank of America, N.A., or another issuer acceptable to Great Basin in its reasonable discretion (the “Issuer”), in the stated amount of $1,800,000 (the “Credit Amount”) and having a one-year term,
subject to annual renewals as determined by the Foundation (the “Term”). The Letter of Credit shall be issued for the benefit of one or more Creditors, as requested by Great Basin and approved by the Foundation. The Letter of Credit
shall permit partial draws. Subject to the terms of the Letter of Credit, Great Basin shall be permitted to deliver the Letter of Credit to one or more Creditors until the expiration of the Term, at which time the Letter of Credit shall expire and
be of no further force or effect. 
 2. Payment of Fee. As consideration for the Foundation causing the Letter of Credit to be
issued, until the expiration of the Term or such time as the Letter of Credit is otherwise terminated and is no longer outstanding and all amounts drawn on the Letter of Credit have been repaid in full, Great Basin shall pay to the Foundation an
amount equal to ten percent (10%) of the Credit Amount per annum (regardless of whether any amount has been drawn on the Letter of Credit), to be paid at the times and in the amounts set forth on Schedule A attached hereto. 

  
 -1- 

 3. Security Agreement. All obligations of Great Basin under this Agreement and the Letter
of Credit, will be secured by a Security Agreement substantially in the form of Exhibit A attached hereto, to be executed by Great Basin in favor of the Foundation and encumbering all of the assets of Great Basin, as more specifically set
forth in such Security Agreement (the “Security Agreement”). The Foundation hereby agrees that upon the request of Onset Financial, Inc. (“Onset”), subject to the consent of the Foundation, which consent will not be
unreasonably withheld, the Foundation will subordinate the lien created by the Security Agreement to the first position lien proposed to be granted by Great Basin in favor of Onset, as referenced in the Security Agreement. 

4. Reimbursement of Costs and Expenses. Great Basin shall be responsible for and shall indemnify the Foundation against, and, upon the
Foundation’s request, pay to the Foundation or as the Foundation directs, any and all fees, costs and expenses (including fees, costs and expenses of legal counsel and other advisors) incurred by the Foundation with respect to the Letter of
Credit, including, without limitation, all amounts drawn on the Letter of Credit, or any collateral related thereto, and any issuance, maintenance and renewal fees charged by the Issuer, which annual issuance and renewal fees are estimated to be
approximately one percent (1%) of the Credit Amount per annum. Without limiting the generality of this Section 4, Great Basin will pay all amounts payable by the Foundation to the Issuer immediately upon such amounts becoming due and
payable. 
 5. No Modification; Entire Agreement. This Agreement and the agreements contained herein shall not be amended, modified
or terminated without the written consent of all of the Parties. This Agreement, together with the Security Agreement, constitute the entire agreement between the Parties with respect to the subject matter hereof and supersede all prior arrangements
and understandings of the Parties with respect thereto. 
 6. No Third Party Beneficiaries. None of the provisions of this Agreement
shall be for the benefit of or be enforceable by any creditor of any of the parties hereto or operate for the benefit of or be enforceable by any third party. 

7. Governing Law. THIS AGREEMENT, AND ALL ACTIONS (WHETHER AT LAW, IN CONTRACT OR IN TORT) THAT MAY BE BASED UPON, ARISE OUT OF OR
RELATE TO THIS AGREEMENT, OR THE NEGOTIATION, EXECUTION OR PERFORMANCE HEREOF SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF UTAH WITHOUT REGARD TO PRINCIPLES OF CONFLICTS OF LAW. 

8. No Assignment. No assignment or transfer of any rights or obligations under this Agreement shall be permitted without the prior
written consent of the Parties. Any transfer or assignment in violation of this Section 8 shall be null and void. 
 9. No
Waiver. No failure on the part of any Party to exercise, and no delay of any Party in exercising, any right, remedy or power hereunder shall operate as a waiver thereof, nor shall any single or partial exercise by such Party of any right, remedy
or power hereunder preclude any other or future exercise of any right, remedy or power hereunder. 

  
 -2- 

 10. Counterparts. This Agreement may be executed in counterparts, each of which shall be
deemed an original, but all of which together shall be deemed to be one and the same agreement. Delivery of an executed signature page to this Agreement by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same
legal effect as delivery of an original signed copy of this Agreement. 
 [Remainder of Page Left Blank Intentionally; Signature Page
Follows] 

  
 -3- 

 IN WITNESS WHEREOF, the Parties hereto have executed this Agreement on the date and at the place
set forth their respective signatures. 
  

					
	Sincerely,
	
	 UTAH AUTISM FOUNDATION,
 a Utah
non-profit corporation

		
	By:	 	/s/ David R. Spafford
		 	  

		 	Name:	 	David R. Spafford
		 	Title:	 	President
	
	 GREAT BASIN SCIENTIFIC, INC.,
 a
Delaware corporation

		
	By:	 	/s/ Ryan Ashton
		 	  

		 	Name:	 	Ryan Ashton
		 	Title:	 	President, CEO

  
 -4- 

 Schedule A 

Each month, Great Basin shall pay $15,000 to the Foundation on or before the tenth day of such month. 

 Exhibit A 

Form of Security Agreement 

[See Exhibit 10.19]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00234-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00234-of-00352.parquet"}]]